We feel now is a pretty good time to analyse PYC Therapeutics Limited's ( ASX:PYC ) business as it appears the ...

PYC Therapeutics Ltd. Annual stock financials by MarketWatch. View the latest PYC financial statements, income statements and financial ratios.

The latest update is out from PYC Therapeutics Limited ( (AU:PYC)). PYC Therapeutics Limited has notified the market that it will issue 2,000,000 unlisted options as unquoted equity securities, ...

PYC Therapeutics Limited ( (AU:PYC)) has issued an announcement. PYC Therapeutics Limited has issued 2.5 million unlisted employee options under its employee incentive scheme, effective 5 January 2026 ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics Limited has announced a significant breakthrough in treating Phelan-McDermid Syndrome (PMS), a rare neurodevelopmental ...

Zero-debt allows substantial financial flexibility, especially for small-cap companies like Physiomics Plc (LON:PYC), as the company does not have to adhere to strict debt covenants. However, it also ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics has dosed its first patient in a clinical trial for its innovative drug candidate, PYC-001, which aims to treat Autosomal ...

PYC Therapeutics (ASX: PYC) presented its Q2 2025 investor webinar on May 30, outlining progress across its genetic medicine pipeline while facing continued market skepticism. The company’s stock ...

PYC Therapeutics raised AU$40 million of an anticipated AU$74 million (US$48.6 million) capital raise to advance three candidates, including lead candidate VP-001, which could potentially be the first ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.